
AngioDynamics (ANGO) Stock Forecast & Price Target
AngioDynamics (ANGO) Analyst Ratings
Bulls say
AngioDynamics Inc has been successfully expanding its Auryon product's customer base in both out-of-hospital and hospital settings, which is positively impacting average selling prices (ASP). The company is also on track to enhance its gross margins to 52.5% through accelerated manufacturing initiatives and a favorable shift toward higher Med-Tech revenue. Additionally, management projects sustained growth driven by new customer acquisitions, increased utilization within existing accounts, and a recent ability to raise pricing on its offerings.
Bears say
AngioDynamics Inc is facing significant financial challenges, including anticipated tariff headwinds estimated between $4 million and $6 million, which could negatively impact revenue projections. Additionally, the company expects its second half of fiscal year 2026 inventory to be pressured by rising raw material costs, indicating potential margin shrinkage. Despite recent successes with capital sales and strong demand for NanoKnife disposables, these operational and cost pressures could undermine the company’s long-term financial stability.
This aggregate rating is based on analysts' research of AngioDynamics and is not a guaranteed prediction by Public.com or investment advice.
AngioDynamics (ANGO) Analyst Forecast & Price Prediction
Start investing in AngioDynamics (ANGO)
Order type
Buy in
Order amount
Est. shares
0 shares